Mesenchymal stem cells and bisphosphonate‐related osteonecrosis of the jaw: the future?

Hematopoietic stem cells and bisphosphonate‐related osteonecrosis of the jaw

“…We share the vision of the authors regarding the great potential of hematopoietic stem cells to treat osteonecrosis of the jaws (Cella et al, 2011;Gonzalvez-Garcia et al, 2012). The unique characteristics of bone marrow cells include homing to bone spaces and pluripotency -the capability of producing various cell lineages including macrophages and osteoclasts (Voermans et al, 2001).…”

“…(Gonzalvez-Garcia et al, 2012). This opinion paper integrates the available knowledge about hematopoiesis and the characteristics of hematopoietic stem cells and presents a potential clinical application.…”

“…We read with great interest the Letter to the Editor entitled 'Mesenchymal stem cells and bisphosphonate-related osteonecrosis of the jaw: the future?' (Gonzalvez-Garcia et al, 2012). This opinion paper integrates the available knowledge about hematopoiesis and the characteristics of hematopoietic stem cells and presents a potential clinical application.…”

Cytoprotective effects of melatonin on zoledronic acid-treated human mesenchymal stem cells in vitro

“…Their functional properties have been proven by several experimental and clinical studies using autologous bone marrow stem cells (BMMSCs) for wound healing, cell architecture repair, and recovery of local blood flow in injured and ischemic tissues (Sun et al, 2009). In addition, the osteogenic plasticity of BMMSCs is a very interesting and useful property in the field of reconstructive bone surgery, including oral and maxillofacial surgery (Gonz alvez- García et al, 2012García et al, , 2013.…”

Osteonecrosis of the jaw from bone anti‐resorptives: impact of skeletal site‐dependent mesenchymal stem cells

“…Recently, two Letters to the Editor addressed the use of bone mesenchymal (Gonzalvez-Garcia et al, 2012) and hematopoietic (Elad et al, 2012) stem cells in the management of osteonecrosis of the jaw (ONJ), a common complication of bone anti-resorptive therapies. Clearly, bisphosphonates and denosumab are highly efficacious in controlling dysregulated bone remodeling in osteoporosis, Paget’s disease, multiple myeloma and skeletal events of cancer metastasis, however ONJ is still an unpredictable recalcitrant oral complication (Fusco et al, 2011, Stopeck et al, 2010).…”